Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.47 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.46 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19127905 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL29508172 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL5084837 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL5204684 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL16884634 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL835295 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL2825440 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL2825437 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL835150 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL21376096 | 0.91 | MAPT (0.64) | MAPTEPHX2CNR2ALDH1A1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887900-B2 | Nematicidal compositions and methods | DIVERGENCE, INC. (US) | 2005-05-03 | — | — | US | claimed |
| US-20030176402-A1 | Nematicidal compositions and methods | MONSANTO TECHNOLOGY LLC | 2003-09-18 | — | — | US | claimed |
| US-20030166714-A1 | Nematicidal compositions and methods | MONSANTO TECHNOLOGY LLC | 2003-09-04 | — | — | US | claimed |
| EP-3967299-B1 | PKC ACTIVATORS AND COMBINATIONS THEREOF FOR TREATING ALZHEIMER DISEASE | COGNITIVE RES ENTERPRISES INC (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025056602-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF IN TREATMENT OF CONDITIONS AND DISEASES RELATED TO ELASTIN DEFICIENCY AND/OR AGING | Elastin Biosciences Ltd. (GB) | 2025-03-20 | — | — | WO | disclosed |
| US-20250064776-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS USING PKC ACTIVATORS | Synaptogenix, Inc. (US) | 2025-02-27 | — | — | US | disclosed |
| WO-2024258981-A2 | METHODS FOR REPAIRING NERVE DAMAGE USING PKC ACTIVATING THERAPEUTIC AGENTS | Synaptogenix, Inc. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240408056-A1 | METHODS FOR REPAIRING NERVE DAMAGE USING PKC ACTIVATING THERAPEUTIC AGENTS | SYNAPTOGENIX INC (US) | 2024-12-12 | — | — | US | disclosed |
| EP-2892509-B1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LAUREN SCIENCES LLC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240390324-A1 | METHODS OF TREATING AND PREVENTING NEURODEGENERATIVE DISEASES WITH HGF ACTIVATING COMPOUNDS | Synaptogenix, Inc. (US) | 2024-11-28 | — | — | US | disclosed |
| US-20240180869-A1 | TREATMENT OF MULTIPLE SCLEROSIS USING PKC ACTIVATORS | Synaptogenix, Inc. (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2003075656-A2 | NEMATICIDAL FATTY ACID AND FATTY ACID ESTER RELATED COMPOUNDS | DIVERGENCE, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
| US-20030166714-A1 | Nematicidal compositions and methods | MONSANTO TECHNOLOGY LLC | 2003-09-04 | — | — | US | disclosed |
| WO-2003047499-A2 | AMPHIPHILIC COMPOUNDS AND VESICLES/LIPOSOMES FOR ORGAN-SPECIFIC DRUG TARGETING | BEN GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) | 2003-06-12 | — | — | WO | disclosed |
| EP-1309698-A2 | A CYTOCHROME P450 ENZYME ASSOCIATED WITH THE SYNTHESIS OF DELTA-12 -EPOXY GROUPS IN FATTY ACIDS OF PLANTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20030066103-A1 | Cytochrome P450 enzyme associated with the synthesis of delta12-epoxy groups in fatty acids of plants | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-04-03 | — | — | US | disclosed |
| WO-2002055011-A2 | AMPHIPHILIC DERIVATIVES FOR THE PRODUCTION OF VESICLES, MICELLES AND COMPLEXANTS, AND PRECURSORS THEREOF | UNIV BEN GURION (IL) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002008269-A2 | A CYTOCHROME P450 ENZYME ASSOCIATED WITH THE SYNTHESIS OF Δ12-EPOXY GROUPS IN FATTY ACIDS OF PLANTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2002-01-31 | — | — | WO | disclosed |
| EP-0977866-A1 | FATTY ACID MODIFYING ENZYMES FROM DEVELOPING SEEDS OF $i(VERNONIA GALAMENENSIS) | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998056922-A1 | FATTY ACID MODIFYING ENZYMES FROM DEVELOPING SEEDS OF $i(VERNONIA GALAMENENSIS) | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180869-A1 | TREATMENT OF MULTIPLE SCLEROSIS USING PKC ACTIVATORS | MAPK7, PRKAR2B, MAPK13 | MAPT 1763/4885EPHX2 3536/4885CNR2 495/4885 |
| US-20240390324-A1 | METHODS OF TREATING AND PREVENTING NEURODEGENERATIVE DISEASES WITH HGF ACTIVATING COMPOUNDS | BDNF, HGF, NGF | MAPT 66/4885EPHX2 2926/4885CNR2 3738/4885 |
| US-20250064776-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS USING PKC ACTIVATORS | PARK7, PMAIP1, SMN1; SMN2 | MAPT 1023/4885EPHX2 4816/4885CNR2 3712/4885 |
| US-20030166714-A1 | Nematicidal compositions and methods | SCD, FADS2, ELOVL3 | MAPT 4347/4885EPHX2 230/4885CNR2 229/4885 |
| US-20240408056-A1 | METHODS FOR REPAIRING NERVE DAMAGE USING PKC ACTIVATING THERAPEUTIC AGENTS | PRKAR2B, PRKAR2A, PRKCB | MAPT 4311/4885EPHX2 1827/4885CNR2 972/4885 |
| US-20030176402-A1 | Nematicidal compositions and methods | FADS2, FASN, SCD | MAPT 4351/4885EPHX2 150/4885CNR2 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.